{
  "docId": "019dd923-622c-750b-8b9a-101b5bfde4b8",
  "docSlug": "a70fecd99534",
  "documentTitle": "Berkeley Lights (BLI)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-09-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 156,
  "pageCount": 158,
  "prevPage": 155,
  "nextPage": 157,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses expert testimony to frame Abcellera as a disruptive competitor to BLI.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-101b5bfde4b8/156",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8#slide-156",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Abcellera’s system has similar capabilities, delivered via a less expensive service model that avoids a $2MM capital purchase and the maintenance requirements of a complex platform",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-2042-70a9-a1b0-a2a3a0bfc19e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "list",
      "text": "Abcellera’s system has similar capabilities, delivered via a less expensive service model that avoids a $2MM capital purchase and the maintenance requirements of a complex platform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34e8d414-9cfb-4159-a1bc-8985b79b5c3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Abcellera is a key competitor; productizing single cell screening as BLI tries to do is “so damn hard” that customers outsource to Abcellera and others like HiFi who sells it as a service",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f516919-24fc-4abe-8569-d30b567e5da6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "list",
      "text": "Abcellera has already eclipsed BLI in size and offer “exactly the same workflow”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83e8bf07-5efa-4f42-b36e-11b7200b5991",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.87,
        "x": 0.08,
        "y": 0.8
      },
      "kind": "quote",
      "text": "“And, of course, then there’s the service providers like AbCellera, which is already doing two or three-fold Berkeley Lights revenue, has a slightly different technical approach, but effectively, it does exactly the same workflow—screens cells for antibodies, picks out the ones that are making the relevant antibody and allows the research and development teams to then go and further characterize those antibodies.” -Former executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f9477b6-37f7-4ecd-b8ab-2a1c9a7766dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.87,
        "x": 0.08,
        "y": 0.36
      },
      "kind": "quote",
      "text": "“AbCellera is a big one. In terms of a technology competitor, like think of who else can do that single-cell secretion assay and then identify that cell. AbCellera can do that, but it’s so damn hard that they could not productize it, so they did a very good job in making it as a service...Customers who want to just outsource everything; they go to AbCellera. For customers who want to do it by themselves, have the flexibility, they go for Berkeley Lights. Sphere, HiFi. HiFi is a decent company that can actually do single cell in a droplet, but I think that’s also pretty hard that they could not productize, so they’re just running it as a service.” -Former senior scientist",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f9f2913-64a6-4c19-b6fd-34afd5123291",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.87,
        "x": 0.08,
        "y": 0.6
      },
      "kind": "quote",
      "text": "“For antibody discovery, there is obviously AbCellera that has a similar system for – it’s a comparable system for evaluation of single cells. AbCellera also is based on a microfluidic device. But again, AbCellera’s business model is different because they don’t sell platforms. They basically develop everything internally, so they have customers that give them mice, rabbits, or anything like cells to identify antibody clones, and they do it internally, so they don’t have to support the maintenance of the platform in a field.” -Former scientist",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3dcaada-65a2-489c-b254-0b0bedcef8b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"AbCellera is a big one. In terms of a technology competitor, like think of who else can do that single-cell secretion assay and then identify that cell. AbCellera can do that, but it's so damn hard that they could not productize, so they did a very good job in making it as a service...Customers who want to just outsource everything; they go to AbCellera.\" — Former senior scientist; \"For antibody discovery, there is obviously AbCellera that has a similar system for – it's a comparable system for evaluation of single cells. AbCellera also is based on a microfluidic device. But again, AbCellera's business model is different because they don't sell platforms.\" — Former scientist; \"And, of course, then there's the service providers like AbCellera, which is already doing two or three-fold Berkeley Lights revenue, has a slightly different technical approach, but effectively, it does exactly the same workflow—screens cells for antibodies, picks out the ones that are making the relevant antibody and allows the research and development teams to then go and further characterize those antibodies.\" — Former executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2042-70a9-a1b0-a46bd06f1914",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "697b092d-ec06-4852-8cc4-105f7d007dc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Three former employees pointed to Abcellera (ticker: ABCL) as BLI’s key competitor. With $5B in market cap, a former scientist stated it has already eclipsed BLI in size and offers “exactly the same workflow.” A former scientist and an ex-executive each described Abcellera’s service-based business model, which avoids BLI’s upfront $2MM price tag.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f872940-f8eb-42d7-8ac8-4b67f0b68674",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Part 2) Former BLI employees/executives: Competition from cheaper, better alternatives has already rendered BLI irrelevant",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d16ab76-21d5-4669-9ca8-42439c46e65e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Anadiplosis",
      "slug": "anadiplosis",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "347fbea3-a6cf-46b7-af51-b8f084c494bd",
      "evidence": "The use of repetition in quotes and bullet points emphasizes the competitive threat posed by Abcellera.",
      "confidence": 0.7
    },
    {
      "name": "Villain slide",
      "slug": "villain-slide",
      "agent": null,
      "layer": "slide",
      "matchId": "863f820c-ccc2-4118-94ec-52e84e4be730",
      "evidence": "The slide presents a critical view of Abcellera as a competitor, highlighting its capabilities and contrasting it with BLI.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}